Citation Impact
Citing Papers
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
2009 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Implications of Thyroglobulin Antibody Positivity in Patients with Differentiated Thyroid Cancer: A Clinical Position Statement
2013
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice
2018 Standout
Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases
2004
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review
2005
Osteoporosis
2019 Standout
Guidelines for radioiodine therapy of differentiated thyroid cancer
2008
The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease
2016
Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer
2001 Standout
Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”
2007
Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan
2006
Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma
2008
Trial of Tocilizumab in Giant-Cell Arteritis
2017 Standout
Long-Term Survival in Differentiated Thyroid Cancer Is Worse After Low-Activity Initial Post-Surgical131I Therapy in Both High- and Low-Risk Patients
2014
Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates
2003
Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report
2005
Pacientes tratados por carcinoma diferenciado de tiroides con rastreos de 131I negativos y niveles de tiroglobulina elevada. Una evolución posible
2007
Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer
2011
Well‐differentiated thyroid carcinoma: The role of post‐operative radioactive iodine administration
2012
Potential Use of Recombinant Human Thyrotropin in the Treatment of Distant Metastases in Patients with Differentiated Thyroid Cancer
2012
Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole‐body scan: comparative study
2003
Serum thyroglobulin concentrations predict disease‐free remission and death in differentiated thyroid carcinoma
2006
Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin
2003
Quantitative Shear Wave Velocity Measurement on Acoustic Radiation Force Impulse Elastography for Differential Diagnosis between Benign and Malignant Thyroid Nodules: A Meta-analysis
2015
European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS
2017 Standout
Thyroid lobe ablation with iodine-131 in patients with differentiated thyroid carcinoma
2013
Dosimetry and thyroid cancer: the individual dosage of radioiodine
2010
Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients
2006
Management of Differentiated Thyroid Cancer with Rising Thyroglobulin and Negative Diagnostic Radioiodine Whole Body Scan
2010
How reliable is secondary risk stratification with stimulated thyroglobulin in patients with differentiated thyroid carcinoma?
2013
Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level
2011
Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer
2013
A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of131I and review of the literature: implications for sequential treatments
2005
ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee
2017 Standout
Influence of Diagnostic Radioiodines on the Uptake of Ablative Dose of Iodine-131
1994
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
2006 Standout
No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer
2009
Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma
2011
The role of elastography in thyroid ultrasonography
2016
Lymph Node Ratio of the Central Compartment is a Significant Predictor for Locoregional Recurrence After Prophylactic Central Neck Dissection in Patients with Thyroid Papillary Carcinoma
2013
Should ‘low‐risk’ thyroid cancer patients with residual thyroglobulin be re‐treated with iodine 131?
2006
The success rate of I-131 ablation in differentiated thyroid cancer: comparison of uptake-related and fixed-dose strategies
2008
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
2017 Standout
Diagnostic value of serum thyroglobulin measurements in the follow‐up of differentiated thyroid carcinoma, a structured meta‐analysis
2004
Recombinant Human Thyrotropin-Assisted Radioiodine Therapy for Patients with Metastatic Thyroid Cancer Who Could Not Elevate Endogenous Thyrotropin or Be Withdrawn from Thyroxine
2006
Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce
2006 Standout
Thyroid Imaging Reporting and Data System Risk Stratification of Thyroid Nodules: Categorization Based on Solidity and Echogenicity
2016
The Utility of I-123 Pretherapy Scan in I-131 Radioiodine Therapy for Thyroid Cancer
2012
2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum
2017 Standout
131I Activity for Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Systematic Review
2006
Opportunistic Screening for Osteoporosis Using Body CT Scans Obtained for Other Indications: the UW Experience
2017
Radioiodine therapy for patients with differentiated thyroid cancer after thyroidectomy: direct comparison and network meta-analyses.
2013
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
2006
Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
2005
Diagnostic Accuracy of Sonoelastography in Detecting Malignant Thyroid Nodules: A Systematic Review and Meta-Analysis
2014
A Comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-Iodine Administered Doses for Recombinant Thyrotropin-Stimulated Postoperative Thyroid Remnant Ablation in Differentiated Thyroid Cancer
2007
Response of thyroglobulin to radioiodine therapy in thyroglobulin-elevated negative iodine scintigraphy (TENIS) syndrome.
2011
Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer
2010
Empiric High-Dose 131-Iodine Therapy Lacks Efficacy for Treated Papillary Thyroid Cancer Patients with Detectable Serum Thyroglobulin, but Negative Cervical Sonography and 18F-Fluorodeoxyglucose Positron Emission Tomography Scan
2010
Chromosome Translocation Frequency after Radioiodine Thyroid Remnant Ablation: A Comparison between Recombinant Human Thyrotropin Stimulation and Prolonged Levothyroxine Withdrawal
2009
Radioiodine Therapy in Benign Thyroid Diseases: Effects, Side Effects, and Factors Affecting Therapeutic Outcome
2012
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules - 2016 Update Appendix
2016 Standout
A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.
2002
Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases
2009
Guidelines for the management of thyroid cancer
2014 Standout
Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review
2005
Ultrasound Elastography: Review of Techniques and Clinical Applications
2017 Standout
Thyroglobulin before Ablation and Correlation with Posttreatment Scanning
2005
Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
2005
FEA to Measure Bone Strength: A Review
2016
The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I
2009
Cancer treatment and survivorship statistics, 2014
2014 Standout
Works of Bart de Keizer being referenced
Opportunistic screening for osteoporosis on routine computed tomography? An external validation study
2015
FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis
2013
Qualitative elastography can replace thyroid nodule fine-needle aspiration in patients with soft thyroid nodules. A systematic review and meta-analysis
2015
Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients
2005
Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin
2001
Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy
2000
High Failure Rates After 131I Therapy in Graves Hyperthyroidism Patients With Large Thyroid Volumes, High Iodine Uptake, and High Iodine Turnover
2013
The Role of Routine Diagnostic Radioiodine Whole-Body Scintigraphy in Patients with High-Risk Differentiated Thyroid Cancer
2010
Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy
2002
Not the Number but the Location of Lymph Nodes Matters for Recurrence Rate and Disease‐Free Survival in Patients with Differentiated Thyroid Cancer
2012
Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
2004
Favorable role of interleukin 10 in patients with polymyalgia rheumatica.
1999
Value of diagnostic radioiodine scintigraphy and thyroglobulin measurements after rhTSH injection
2009